GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

LSL Pharma Group LSL.V · CAD

Consumer Staples · TSX Venture · 🇨🇦 Canada

Compare

0.31

-1.61%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About LSL Pharma Group

Its shares trade on TSX Venture under the ticker LSL.V. It has been listed since 8 March 2011. In the fiscal year to 31 December 2025, it reported revenue of C$28.7m and a net loss of C$2.8m. At that date it held total assets of C$74.7m and shareholders' equity of C$27.0m.

LSL Pharma Group, Inc. operates as a pharmaceutical company. The company is headquartered in Boucherville, Quebec. The company went IPO on 2011-03-08. The firm is specializing in the development, manufacturing and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The Company’s subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Personal Care Products
Listed since
8 Mar 2011

Leadership

Pay as last reported

  • Mr. Francois RobergeChairman of the Board, President, Chief Executive Officer, since 2023C$302,000
  • Mr. Luc MainvilleChief Financial Officer, Executive Vice President, since 2023C$268,000
  • Mr. Francis ChenardChief Operating Officer, Senior Vice PresidentC$183,936
  • Mr. Louis LaflammeDirector
  • Ms. Diane BeaudryIndependent DirectorC$3,250
  • Mr. Frank DellaferaIndependent DirectorC$2,500
  • Mr. Stuart FowlerIndependent DirectorC$2,750
  • Mr. Pierre LafreniereIndependent DirectorC$3,250
  • Mr. Mario ParadisIndependent DirectorC$4,000
  • Mr. Giuseppe SoccodatoIndependent DirectorC$3,250

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • LSL Pharma Group specializes in natural health products and dietary supplements in solid dosage forms.
  • Steri-Med Pharma Inc. develops sterile ophthalmic pharmaceutical products for eye care.
  • LSL Laboratory Inc. focuses on manufacturing and distributing natural health products in Canada.

Weaknesses

  • LSL Pharma Group has no subsidiaries in the United States market.
  • The company's operations are limited to Canada and Quebec regions.
  • LSL Laboratory Inc. does not have a global distribution network.

Opportunities

  • LSL Pharma Group can expand into the U.S. market for natural health products.
  • The growing demand for dietary supplements in Canada presents new opportunities.
  • Steri-Med Pharma Inc. can target the expanding ophthalmic pharmaceutical market.

Threats

  • LSL Pharma Group faces competition from established Canadian pharmaceutical companies.
  • The regulatory environment for dietary supplements may become stricter in Canada.
  • Steri-Med Pharma Inc. could encounter supply chain disruptions in ophthalmic products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.